Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Obstet Gynecol ; 136(4): 774-781, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32925621

RESUMO

OBJECTIVE: To assess whether mifepristone pretreatment adversely affects the cost of medical management of miscarriage. METHODS: Decision tree analyses were constructed, and Monte Carlo simulations were run comparing costs of combination therapy (mifepristone and misoprostol) with monotherapy (misoprostol alone) for medical management of miscarriage in multiple scenarios weighing clinical practice, patient income, and surgical evacuation modalities for failed medical management. Rates of completed medical evacuation for each were obtained from a recent randomized controlled trial. RESULTS: In every scenario, combination therapy offered a significant cost advantage over monotherapy. Using a Monte Carlo analysis, cost differences favoring combination therapy ranged from 6.3% to 19.5% in patients making federal minimum wage. The cost savings associated with combination therapy were greatest in scenarios using a staged approach to misoprostol administration and in scenarios using in-operating room dilation and curettage as the only modality for uterine evacuation, a savings of $190.20 (99% CI 189.35-191.07) and $217.85 (99% CI 217.19-218.50) per patient in a low-income wage group, respectively. A smaller difference was seen in scenarios using in-office manual vacuum aspiration to complete medical management failures. As patients' wages increased, the difference in cost between combination therapy and monotherapy increased. CONCLUSION: Mifepristone combined with misoprostol is, overall, more cost effective than monotherapy, and therefore cost should not be a deterrent to its adoption in the management of miscarriage.


Assuntos
Aborto Incompleto , Aborto Induzido , Quimioterapia Combinada , Mifepristona , Misoprostol , Abortivos/administração & dosagem , Abortivos/economia , Aborto Incompleto/induzido quimicamente , Aborto Incompleto/economia , Aborto Incompleto/cirurgia , Aborto Induzido/efeitos adversos , Aborto Induzido/economia , Aborto Induzido/métodos , Análise Custo-Benefício , Dilatação e Curetagem/economia , Dilatação e Curetagem/métodos , Quimioterapia Combinada/economia , Quimioterapia Combinada/métodos , Feminino , Humanos , Mifepristona/administração & dosagem , Mifepristona/economia , Misoprostol/administração & dosagem , Misoprostol/economia , Método de Monte Carlo , Padrões de Prática Médica , Gravidez
2.
Fertil Steril ; 88(4): 1014-5, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17412339

RESUMO

Our objective was to survey training in ET techniques among fellows, its perceived importance, and potential barriers to ET training during fellowship. Although ET training remains an important issue for most fellows and recent graduates, 44% of respondents did not receive this training during their fellowship.


Assuntos
Transferência Embrionária , Bolsas de Estudo , Obstetrícia/educação , Estudos Transversais , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA